MD Anderson Cancer Center

Latest Headlines

Latest Headlines

Researchers zero in on biomarker for early diagnosis of ovarian cancer

Investigators say that a biomarker in the blood--carbohydrate antigen 125, or CA125--offers a shot at a relatively low-cost approach to identifying ovarian cancer  at an early stage, while the chances of survival are much higher.

Docs call drugmakers 'profiteers' for costs of cancer meds

Sanofi is not very popular among its peers today. Its decision last year to halve the cost of its colon cancer drug Zaltrap in the face of high-profile criticism has inspired more than a 100 top docs from around the world to protest the astronomical costs of cancer drugs, calling the prices immoral and tagging drugmakers as profiteers.

Biomarker for liver problems also predicts lung cancer likelihood

Call it biomarker repurposing. Researchers have identified a compound produced by the body that can flag smokers at increased risk for lung cancer--a substance long used to gauge liver function.

Add a drop of blood, and this tiny Dx device tests 50 things at once

Researchers in Texas have come up with a device that's essentially an adaptable diagnostic tool. How so? It can measure 50 different things at once from a single blood drop.

Preclinical data snags GlaxoSmithKline's attention in $335M cancer immunotherapy deal

Preclinical research into cancer immunotherapy at the University of Texas MD Anderson Cancer Center has caught the attention GlaxoSmithKline. This has resulted in the signing of a research collaboration and licensing agreement that could be worth $335 million in upfront, milestone and royalty payments.

Biomarker helps brain cancer snack on sugar

Researchers at the MD Anderson Cancer Center have found a protein, PKM2, that could act as a biomarker in patients with glioblastoma multiforme and have found a new role for a type of kinase inhibitor not tested in this condition so far.

CTCs predict survival in breast cancer

In a study from the University of Texas MD Anderson Cancer Center, researchers have found a role for CTCs as a marker to predict the outcome of early stage breast cancer.

Accelrys software to support efforts in Texas to study rare cancers

The San Diego-based provider of R&D software has inked a 5-year deal with the Gulf Coast Consortia for Quantitative Biomedical Sciences, which involves researchers from multiple fields and centers in Texas who are teaming up to advance treatment and prevention of diseases such as rare cancers.

Carbon nanoparticles charge up old cancer treatment to powerful effect

Carbon nanoparticles are galloping to the rescue once again. Scientists are exploring their use as a booster ingredient to enhance the effectiveness of an existing treatment for head-and-neck cancer....

Humans to test T-cell treatment that subdued canine lymphoma

Dogs are often loyal and are great companions. Now, they're also trailblazers in cancer research. An innovative new lymphoma treatment helped prolong the lives of dogs with the disease, and it...